Cell penetration: Scope and limitations by the application of cell-penetrating peptides

Journal of Peptide Science

Volumn 20, Issue 10, 2014, Pages 760-784

  Reissmann, Siegmund ^a,b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Jena Bioscience GmbH   (Germany)

Author keywords

activatable CPPs; amino acid sequences; antibodies; azurin; cargos proteins; cell and tissue selectivity; cell penetrating peptides; cellular uptake process; conformations; coupling to dendrimers; enzymes; intracellular concentrations; intracellular trafficking; maurocalcine; multifunctional nanoparticles; oncogenase; pH pO2 sensitive CPPs; preclinical and clinical studies; RNA mimics; siRNA; uptake efficiency

Indexed keywords

CELL PENETRATING PEPTIDE; DENDRIMER; DNA; HYBRID PROTEIN; NANOPARTICLE; NUCLEOTIDE; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; PEPTIDES AND PROTEINS; RNA; SMALL INTERFERING RNA; VIRUS VECTOR;

BIOCHEMICAL ANALYSIS; BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; CELL MEMBRANE; CELL ORGANELLE; CELL SELECTION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONJUNCTIVA; DRUG DELIVERY SYSTEM; ELECTROPORATION; ENDOSOME; GENE THERAPY; HOST CELL; HUMAN; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; MEMBRANE STABILIZATION; NERVE CELL; NONHUMAN; PHYSIOLOGICAL PROCESS; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN STRUCTURE; REACTION ANALYSIS; REVIEW; SKIN; TISSUE SECTION; VIRUS PARTICLE; ADVERSE EFFECTS; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; ENDOCYTOSIS; PROCEDURES; PROTEIN TRANSPORT; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GENETIC THERAPY; HUMANS; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PROTEIN TRANSPORT; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908274199     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2672     Document Type: Review

References (316)

1. Handbook of Cell-penetrating Peptides, Langel Ü, (ed.). CRC Taylor & Francis: Boca Raton, London, New York, 2007.
2. Cell-penetrating peptides. Methods and protocols. Methods in Molecular Biology, Series Editor Johm M. Walker, Vol. 683, Langel Ü, (ed.). Springer: New York, Dodrecht, Heidelberg, London 2011.
3. Special Issue "Arginine-rich Peptides". Guest Editor: Shiroh Futaki. Curr. Protein Pept. Sci. 2003; 4 (2).
4. Special Issue "Delivery of therapeutic molecules-from bench to bedside". Biochimica et Biophysica Acta (BBA) Biomembranes 2010; 1798 (12): 2177-2314.
5. Special Issue "Cell penetrating Peptides". Guest Editor: Vladimir P. Torchilin, Pharmaceuticals, 2010-2013.
6. Heitz F, Morris MC, Divita G,. Twenty years of cell-penetrating peptides: from molecular mechanism to therapeutics. Brit. J. Pharmacol. 2009; 157: 195-206.
7. Brasseur R, Divita G,. Happy birthday cell penetrating peptides: already 20 years. Biochim. Biophys. Acta 2010; 1798: 2177-2181.
8. Repke A, Bienert M,. Mast cell activation-a receptor -independent mode of substance P action. FEBS Lett. 1987; 221: 236-240.
9. Oehlke J, Lorenz D, Wiesner B, Bienert M,. Review: studies on the cellular uptake of substance P and lysine-rich, KLA-derived model peptides. J. Mol. Recognit. 2005; 18: 50-59.
10. Oehlke J, Lorenz D, Wiesner B, Bienert M,. Model amphipathic peptides. In Handbook of Cell-penetrating Peptides, Langel Ü, (ed.). CRC-Press: Boca Raton, London, New York, 2007; 43-60.
11. Frankel AD, Pabo CO,. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193.
12. Joliot A, Pernelle C, Deagozini-Bastin H, Prochiantz A,. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 1864-1868.
13. Derossi D, Joliot AH, Chassaing G, Prochiantz A,. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994; 269: 10444-10450.
14. Fominaja J, Weis W,. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. J. Biol. Chem. 1996; 271: 10560-10568.
15. Soomets U, Hallbrink M, Zorko M, Langel Ü,. From galanin and mastoparan to galparan and transportan. Cur.Topics in Pept. & Prot. Res. 1997; 2: 83-113.
16. Lee RW, Rothbard JB, Wender PA,. Guanidinium rich peptide transporters and drug delivery. Current Prot.& Pept. Sci. 2003; 4: 105-124.
17. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y,. Arginine-rich peptides. J. Biol. Chem. 2001; 276: 5836-5840.
18. Vidal P, Chaloin L, Mery J, Lamb N, Lautredou N, Bennes R, Heitz F,. Solid-phase synthesis and cellular localization of a C- or N-terminal labelled peptide. J. Pept. Sci. 1996; 2: 125-133.
19. Chaloin L, Vidal P, Heitz A, van Mau N, Mery J, Divita G, Heitz F,. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. Biochemistry 1997; 36: 11179-11187.
20. Schmidt MC, Rothen-Rutishauser B, Rist B, Beck-Sickinger A, Wunderli-Allenspach H, Rubas W, Sadee W, Merkle HP,. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry 1998; 37: 16582-16590.
21. Krauss U, Merkle HP, Beck-Sickinger AG,. Calcitonin derived peptide carriers are novel tools for selective drug delivery. 2001; Peptides 2000, Proceedings of the European Peptide Symposium, Ed. Martinez J, Fehrentz J-A. pp. 131-132.
22. Foerg C, Ziegler U, Fernandez-Carneado J, Giralt E, Rennert R, Beck-Sickinger AG, Merkle HP,. Decoding the entry of two novel cell-penetrating peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape. Biochemistry 2005; 44: 72-81.
23. Oskolkov N, Arukuusk P, Copolovici D-M, Lindberg S, Margus H, Padari K, Pooga M, Langel Ü,. NickFects, phosphorylated derivatives of transportan 10 for cellular delivery of oligonucleotides. Int. J. Pept. Res. & Therapeutics 2011; 17: 147-157.
24. Ezzat K, EL Andaloussi S, Zaghloul EM, Lehto T, Lindberg S, Moreno PMD, Viola JR, Magdy T, Abdo R, Guterstam P, Sillard R, Hammond SM, Wood MJA, Arzumanov AA, Gait MJ, Smith CIE, Hällbrink M, Langel Ü,. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acid Res. 2011; 39: 5284-5298.
25. Torchilin VP,. TAT peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Advanced Drug Deliv. Rev. 2008; 60: 548-558.
26. Fischer D, von Harpe A, Kunath K, Petersen H, Li Y, Kissel T,. Copolymers of ethylene imine and N-(2-hydroxyethyl)-ethylene imine as tools to study effects of polymer structure on physicochemical and biological properties of DNA complexes. Bioconjug. Chem. 2002; 13: 1124-1133.
27. Olson ES, Tao J, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY,. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 4311-4316.
28. Andreev OA, Karabadzhak AG, Weerakkody D, Andreev GO, Engelman DM, Reshetnyak YK,. pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exists by a different path. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 4081-4086.
29. Sethuraman VA, Bae YH,. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic tumors. J. Control. Rel. 2007; 118: 216-224.
30. Diao Y, Han W, Zhao H, Zhu S, Liu X, Feng X, Gu J, Yao C, Liu S, Sun C, Pan F,. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain. J. Pept. Sci. 2011; 18: 476-486.
31. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui X-S, Kaplan IM, Dowdy SF,. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res. 2005; 65: 10646-10650.
32. Ezzat K, Helmfors H, Tudoran O, Juks C, Lindberg S, Padari K, El-Andaloussi S, Pooga M, Langel Ü,. Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J. 2012; 26: 1172-1180.
33. Letoha T, Keller-Pinter A, Kusz E, Koloszi C, Bozso Z, Toth G, Vizier C, Olah Z, Szilak L,. Cell-penetrating peptide exploited syndecans. Biochim. Biophys. Acta (Biomembranes) 2010; 1798: 2258-2263. DOI: 10.1016/j.bbamem.2010.01.022.
34. Martin I, Teixido M, Giralt E,. Building cell selectivity into CPP-mediated strategies. Pharmaceutics 2010; 3: 1456-1490. DOI: 10.3390/ph3051456.
35. Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, Gupta TK,. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 2009; 69: 537-546.
36. Madani F, Lindberg S, Langel Ü, Futaki S, Gräslund A,. Review article: mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011; Article ID: 414729. doi: 10.1155/2011/414729
37. Ziegler A, Seelig J,. Binding and clustering of glucosaminoglycans: a common property of mono- and multivalent cell-penetrating compounds. Biophys. J. 2008; 94: 2142-2149.
38. Ziegler A,. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv. Drug Deliv. Rev. 2008; 60: 580-597.
39. 9. Biochemistry 2011; 50: 4650-4664.
40. Verdurmen WP, Bovee-Guerts PH, Wadhwani P, Ulrich AS, Hällbrink M, van Kuppevelt TH, Brok R,. Preferential uptake of l-versus d -amino acid cell-penetrating peptides in a cell-type dependent manner. Chem. Biol. 2011; 18: 1000-1010.
41. Bolhassani A,. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery. Biochim. Biophys. Acta 1816; 2011: 232-246.
42. Trabulo S, Cardoso AL, Mano M, De Lima MCP,. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceutics 2010; 3: 961-993.
43. Stewart KM, Horton KL, Kelley SO,. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem. 2008; 6: 2242-2255.
44. Tanaka G, Nakase I, Fukuda J, Masuda F, Oishi S, Shimura K, Kawaguchi Y, Takatani-Nakase T, Langel Ü, Gräslund A, Okawa K, Matsuoka M, Fujii N, Hatanaka Y, Futaki S,. CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV. Chem. & Biol. 2012; 19: 1437-1446.
45. Prudhomme GJ, Glinka J,. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012; 3: 921-939.
46. Laakkonen P, Zhang L, Ruoslahti E,. Peptide targeting of tumor lymph vessels. Ann. N.Y. Acad. Sci. 2008; 1131: 37-43.
47. Ye Y, Chen X,. Integrin targeting for tumor optical imaging. Theranostics 2011; 1: 102-126.
48. Mokhtarieh AA, Kim S, Lee Y, Chung BH, Lee MK,. Novel cell-penetrating peptides with multiple motifs composed of RGD and its analogs. Biochem. Biophys. Res. Com. 2013; 432: 359-364.
49. Bleifuss E, Kammertoens T, Hutloff A, Quarcoo D, Dorner M, Straub P, Uckert W, Hildt E,. The translocation motif of hepatitis B virus improves protein vaccination. Cell. Mol. Lif. Sci. 2006; 63: 627-635.
50. Morris MC, Chaloin L, Mery J, Heitz F, Divita G,. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res. 1999; 27: 3510-3517.
51. Vives E, Brodin P, Lebleu B,. A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997; 272: 16010-16017.
52. Splith K, Neundorf I,. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Europ. Biophys. J. 2011; 40: 387-897.
53. Duchardt F, Ruttekolk IR, Verdurmen WPR, Lortat-Jacob H, Burck J, Hufnagel HR, Fischer R, van der Heuvel M, Lowik DWPM, Vuister GW, Ulrich A, de Waard M, Brok R,. A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency. J. Biol. Chem. 2009; 284: 36099-36108.
54. Rousselle C, Clair P, Lefauconnier J, Kaczorek M, Scherrmann JM, Temsamani J,. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000; 57: 679-686.
55. Chen C, Brok R, Luh F, Chou PJ, Larrik JW, Huang RF, Huang TH,. The solution structure of the active domain of cap18-a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett. 1995; 370: 46-52.
56. Hariton-Gazal E, Rosenbluh J, Graessmann A, Gilon C, Loyter A,. Direct translocation of histone molecules across cell membranes. J. Cell Sci. 2003; 116: 4577-4586.
57. Singh RK, Liang D, Gajjalaiavari UR, Kabaj M-HM, Paik J, Gunjan A,. Excess histone levels mediate cytotoxicity via multiple mechanisms. Cell Cycle 2010; 9: 4236-4244.
58. Liu BR, Huang Y-W, Winiarz JG, Chiang H-J, Lee H-J,. Intracellular delivery of quantum dots mediated by a histidine- and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism. Biomaterials 2011; 32: 3520-3537.
59. Kichler A, Mason AJ, Bechinger B,. Cationic amphipathic histidine-rich peptides for gene delivery. Biochim. Biophys. Acta 2006; 1758: 301-307.
60. Magzoub M, Oglecka K, Pramanik A, Eriksson LEG, Gräslund A,. Membrane perturbation effects of peptides derived from N-termini of unprocessed prion proteins. Biochim. Biophys. Acta (Biomembranes) 2005; 1716: 126-136.
61. Magzoub M, Gräslund A, Pramanik A,. Characterization of prion-derived cell-penetrating peptides in cellular and model membrane systems. Biochem. & Biophys. of Lipids 2006; 175-192.
62. Loefgren K, Wahlstroem A, Lundberg P, Langel Ü, Gräslund A, Bedecs K,. Antiprion properties of prion protein-derived cell-penetrating peptides. FASEB J. 2008; 22: 2177-2184.
63. Magzoub M, Sandgren S, Lundberg P, Oglecka K, Lilja J, Wittrup A, Eriksson LEG, Langel Ü, Belting M, Gräslund A,. N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem. Biophys. Res. Commun. 2006; 348: 379-385.
64. Kempf C, Klausner RD, Weinstein JN, van Renswoude J, Pincus M, Blumenthal R,. Voltage-dependent trans-bilayer orientation of mellitin. J. Biol. Chem. 1982; 257: 2469-2476.
65. Rodrigues M, de la Torre BG, Radis-Baptista G, Santos NC, Andreu D,. Efficient cellular delivery of β-galactosidase mediated by NrTPs, a new family of cell-penetrating peptides. Bioconjugate Chem. 2011; 22: 2339-2344.
66. Nascimento FD, Hayashi MAF, Kerkis A, Oliveira V, Oliveira EB, Radis-Baptista G, Nader HB, Yamane T, dos Santos T, Ivarne L, Kerkis I,. Crotamine mediates gene delivery into cells through binding to heparan sulfate proteoglycans. J. Biol. Chem. 2007; 282: 21349-21360.
67. Radis-Baptista G, Kerkis I,. Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties. Current Pharmacol. Design 2011; 17: 4351-4361.
68. Fajloun Z, Kharrat R, Chen I, Lecomte C, Di Luccio E, Bichet D, El Ayeb M, Rochat H, Allen PD, Pessah IN, De Waard M, Sabatier JM,. Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca(2+) release channel/ryanodine receptors. FEBS Lett. 2000; 469: 179-185.
69. Poillot C, Bichraoui H, Bahemberae E, Andreotti N, Sabatier J-M, Ronjat M, De Waard M,. Small efficient cell-penetrating peptides derived from scorpion toxin maurocalcine. J. Biol. Chem. 2012; 287: 17331-17342.
70. Tisseyre C, Bahemberae E, Dardevet L, Sabatier J-M, Ronjat M, De Waard M,. Cell-penetration properties of a high efficient mini maurocalcine peptide. Pharmaceutics 2013; 6: 320-339.
71. Aroui S, Ram N, Appaix F, Ronjat M, Kenani A, Pirollet F, De Waard M,. Maurocalcine as a non-toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. Pharm. Res. 2009; 26: 836-845.
72. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F, Divita G,. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim. Biophys. Acta 2006; 1758: 384-393.
73. Deshayes S, Plenat T, Aldrian-Herrada G, Divita G, Le Grimellec C, Heitz F,. Primary amphipathic cell penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 2004; 43: 7698-7706.
74. Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F,. Insight into mechanism of internalization of cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry 2004; 43: 1449-1457.
75. Crombez L, Morris MC, Dufort S, Aldrian-Herada G, Nguyen Q, Mc Master G, Coll J-L, Heitz F, Divita G,. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumor growth. Nucleic Acid Res. 2009; 37: 4559-4569.
76. Kurzawa L, Pellerano M, Morris MC,. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells. Biochim. Biophys. Acta 2010; 1798: 2274-2285.
77. Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G,. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Therapy 2009; 17: 95-103.
78. Murata M, Sugahara Y, Takahashi S, Ohnishi S,. pH-dependent membrane fusion activity of a synthetic twenty amino acid peptide with the same sequence as that of the hydrophobic segment of influenca virus hemagglutinin. J. Biochem. 1987; 102: 957-962.
79. Neundorf I, Rennert R, Hoyer J, Schramm F, Loebner K, Kitanovic I, Woelfl S,. Fusion of a short HA2-derived peptide sequence to cell-penetrating peptides improves cytosolic uptake, but enhances cytotoxic activity. Pharmaceutics 2009; 2: 49-65.
80. Andaloussi S, Lehto T, Mäger I, Rosenthal-Aizman K, Oprea JI, Simonson OE, Sork H, Ezzat K, Copolovici DM, Kurrikoff K, Viola JR, Zaghoul EM, Sillard R, Johansson HJ, Hassane FS, Guterstam P, Suhorutsenko J, Moreno PMD, Oskolkov N, Hälldin J, Tedebark U, Metspalu A, Lebleu B, Lehtio J, Smith CIE, Langel Ü,. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systematically in vivo. Nucleic Acids Res. 2011; 39: 3972-3987.
81. Lindberg S, Munoz-Alacon A, Helmfors H, Mosqueira D, Gyllborg D, Tudoran O, Langel Ü,. PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. Int. J. Pharmaceutics 2013; 441: 242-247.
82. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, Harashima H, Sugiura J,. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjugate Chem. 2001; 12: 1005-1011.
83. Mäe M, Andaloussi SE, Lundin P, Oskolkov N, Johansson HJ, Guterstam P, Langel Ü,. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Rel. 2009; 134: 221-227.
84. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Orlov BSV, Perevozchikov AP,. Complex of plasmid DNA with basic domain 47-57 of the HIV-1 TAT protein are transferred to mammalian cells by endocytosis-mediated pathways. J. Biol. Chem. 2003; 278: 42625-42636.
85. Sarojini H, Medepalli K, Terry DA, Alphenaar BW, Wang E,. Localized delivery of DNA to cells by viral collagen-loaded silica colloidal crystals. Biotechniques 2007; 43: 213-221.
86. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC,. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004; 32: e149.
87. Rahmat D, Khan MI, Shahnaz G, Sakloetsakun D, Perera G, Bernkop-Schnuerch A,. Synergistic effects of conjugating cell penetrating peptides and thiomers on non-viral transfection efficiency. Biomaterials 2012; 33: 2321-2326.
88. 2NH amide bond surrogates: potential agents for gene delivery. In Peptides: The Wave of the Future, Lebel M, Houghten RA, (eds). American Peptide Society: San Diego, 2001; 230-231.
89. Kocznan G, Ghose AC, Mookerjee A, Hudecz F,. Methotrexate conjugate with branched polypeptide influences Leishmania donovani infection in vitro and in experimental animals. Bioconjug. Chem. 2002; 13: 518-524.
90. Fischer D, Osburg B, Petersen H, Kissel T, Bickel U,. Effect of poly(ethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mices. Drug Metab. & Dispos. 2004; 32: 983-992.
91. Schlenk F, Grund S, Fischer D,. Recent developments and perspectives on gene therapy using synthetic vectors. Therapeutic Del. 2013; 4: 95-113.
92. Pujals S, Giralt E,. Proline-rich, amphipathic cell-penetrating peptides. Adv. Drug Del.(Rev.) 2008; 60: 473-484.
93. Scocchi M, Tossi A, Gennaro R,. Prolin-rich antimicrobial peptides converging to a non-lytic mechanism of action. Cell. & Mol. Life Sci. 2011; 68: 2317-2330.
94. Farrera-Sinfreu J, Giralt E, Royo M, Albericio F,. Cell-penetrating proline-rich peptidomimetics. Methods in Molecular Biology (Totowa NJ, USA) 2007; 386: 241-267.
95. Sanclimens G, Shen H, Giralt E, Albericio F, Saltzman MW, Royo M,. Synthesis and Screening of a small library of proline-based biodendrimers for use as delivery reagents. Biopolymers (Peptide Science) 2005; 80: 800-814.
96. Eldar-Book A, Miller K, Sanchis J, Lupu R, Vicent MJ,. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011; 32: 3862-3874.
97. Wang C, Luo X, Zhao Y, Han L, Zeng X, Feng M, Pan S, Shirong P, Peng H, Wu C,. Influence of the polyanion on the physico-chemical properties and biological activities of polyanion/DNA/polycation ternary polyplexes. Acta Biomater. 2012; 8: 3014-3026.
98. Martin I, Teixido M, Giralt E,. Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E). ChemBioChem 2011; 12: 896-903.
99. Hansen M, Kilk K, Langel Ü,. Predicting cell-penetrating peptides. Adv. Drug Del. (Rev.) 2008; 60: 572-579.
100. Sanders WS, Johnston CI, Bridges SM, Burgess SC, Willeford KO,. Prediction of cell-penetrating peptides by support vector maschines. PLoS Comput. Biol. 2011; 7: e1002101.
101. Foerg C, Weller K, Reichsteiner H, Nielsen H, Fernandez-Carneado J, Brunisholz R, Giralt E, Merkle HP,. Metabolic cleavage and translocation efficiency of selected cell penetrating peptides: a comparative study with epithelial cell cultures. AAPS J. 2008; 10: 349-359.
102. Rennert R, Wespe C, Beck-Sickinger AG, Neundorf I,. Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. Biochim. Biophys. Acta 2006; 1758: 347-354.
103. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, Gross LA, Tsien RY,. In vivo characterization of activatable cell-penetrating peptides for targeting protease activity in cancer. Integr. Biol. 2009; 1: 382-393.
104. Friedler A, Friedler D, Luedtke NW, Tor Y, Loyter A, Gilon C,. Development of a functional backbone cyclic mimetic of HIV-1 TAT arginine-rich motif. J. Biol. Chem. 2000; 275: 23783-23789.
105. Myrberg H, Lindgren M,., Langel Ü, Protein delivery by cell-penetrating peptide YTA2. Bioconj. Chem. 2007; 18: 170-174.
106. Ma Y, Gong C, Ma Y, Fan F, Luo M, Yang F, Zhang Y-H,. Direct cytosolic delivery of cargoes in vivo by a chimeria consisting of d-and l -arginine residues. J. Control. Rel. 2012; 162: 286-294.
107. Nakase I, Takeuchi T, Tanaka G, Futaki S,. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv. Drug Del. Rev. 2008; 60: 598-607.
108. Padari K, Lorents A, Jokitalo E, Pooga M,. Insight into cell-entry mechanisms of CPPs by electron microscopy. Methods Mol. Biol. 2011; 683: 181-193.
109. Henriques ST,. Biophysics and the way out of the endosomal versus non-endosomal dilemma for cell-penetrating peptide pep-1. Biotechnology (Membrane active peptides) 2010; 9: 377-414.
110. Vesylevsky S, Marrink S-J, Mark AE,. Alternative mechanisms for the interaction of the cell-penetrating peptides penetratin and TAT peptide with lipid bilayers. Biophys. J. 2009; 97: 40-49.
111. Nakase I, Kogure K, Harashima H, Futaki S,. Application of a fusiogenic peptide GALA for intracellular delivery. Methods Mol. Biol. 2011; 683: 525-533.
112. Toriyabe N, Hayashi Y, Harashima H,. The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive srearylated octahistidine. Biomaterials 2013; 34: 1337-1343.
113. Lamaziere A, Burlina F, Wolf C, Chassaing G, Trugnan G,., Ayala-Sanmartin J, Non-metabolic membrane tubulation and permeability induced by bioactive peptides. PLoS One 2007; 2: e201.
114. Ward CM, Acheson N, Seymour LW,. Folic acid targeting of protein conjugates into ascites tumor cells from ovarian cancer patients. J. Drug Target. 2000; 8: 119-123.
115. Qu X-L, Yang C, Zhang J, Ding N, Lu Y, Huang L, Xiang G-Y,. In vitro evaluation of a folate-bovine serum albumin-doxorubicin conjugate. J. Drug Target. 2010; 18: 351-361.
116. Hussain R, Siligardi G,. Fat-free albumin as a novel drug delivery system. Int. J. Pept. Res. & Therap. 2006; 12: 311-315.
117. Lukanowska M, Howl J, Jones S,. Bioportides: bioactive cell-penetrating peptides that modulate cellular dynamics. Biotechnology J. 2013; 8: 918-930.
118. Howl J, Jones S,. Proteomimetic cell penetrating peptides. Int. J. Pept. Res. & Therap. 2008; 14: 359-366.
119. Gomez JA, Gama V, Yoshida T, Sun W, Hayes P, Leskov K, Boothman D, Matsuyama S,. BAX-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. Biochem. Soc. Trans. 2007; 35: 797-801.
120. Gomez JA, Chen J, Ngo J, Hajkova D, Yeh I-J, Gama V, Miyagi M, Matsuyama S,. Cell-penetrating penta-peptides (CP5Ps): measurement of cell entry and protein transduction activity. Pharmaceutics 2010; 3: 3594-3613.
121. Jin E, Zhang B, Sun X, Zhou Z, Ma X, Sun Q, Tang J, Shen Y, van Kirk E, Murdoch WJ,. Acid active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J. Amer. Chem. Soc. 2013; 135: 933-940.
122. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC,. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997; 16: 3008-3017.
123. Chen C-P, Chou J-C, Liu BR, Chang M, Lee H-J,. Transfection and expression of plasmid DNA in plant cells by arginine-rich intracellular delivery peptide without protoplast preparation. FEBS Lett. 2007; 581: 1891-1897.
124. Rudolph C, Plank C, Lausier J, Schillinger U, Mueller RH, Rosenecker J,. Oligomers of the arginine rich-motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 2003; 278: 11411-11418.
125. Cao M-X, Huang J-Q, Yao Q-H, Liu S-J, Wang C-L, Wei Z-M,. Site specific DNA excision in transgenic rice with a cell-permeable Cre-recombinase. Mol. Biotechnol. 2006; 32: 55-63.
126. Tung C-H, Müller S, Weissleder R,. Novel branching membrane translocational peptide as gene delivery vector. Bioorg. & Med. Chem. 2002; 10: 3609-3614.
127. Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R, Jacobs E,. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol.Ther. 2002; 5: 104-114.
128. Arukuusk P, Pärnaste L, Oskolkov N, Copolovici D-M, Margus H, Padari K, Möll K, Maslovskaja J, Tegova R, Kivi G, Tover A, Pooga M, Ustav M, Langel Ü,. New generation of efficient peptide-based vectors, Nick-Fects, for the delivery of nucleic acids. Biochim. Biophys. Acta (Biomembranes) 1828; 2013: 1365-1373.
129. Kuriyama S, Taguchi Y, Nishimura K, Mizuguchi K, Kobayashi K, Katayama Y, Yanagibashi K, Niidome T,. Peptide vector for gene delivery with high affinity for phosphatidylserine. J. Pept. Sci. 2006; 12: 626-632.
130. Paul RW, Weisser KE, Loomis A, Sloane DL, Lafoe D, Atkinson EM, Overell RW,. Gene transfer using a novel fusion protein GAL4/Invasin. Hum. Gene Ther. 1997; 8: 1253-1262.
131. Kim E-S, Yang S-W, Hong D-K, Kim W-T, Kim H-G, Lee S-K,. Cell-penetrating DNA-binding protein as a safe and efficient naked DNA delivery carrier in vitro and in vivo. Biochem. Biophys. Res. Com. 2010; 392: 9-15.
132. Lorents A, Kodavali KK, Oskolkov N, Langel Ü, Hällbrink M, Pooga M,. Cell-penetrating peptides split into two groups based on modulation of intracellular calcium concentration. J. Biol. Chem. 2012; 287: 16880-16889.
133. Palm-Apergi C, Lorents A, Padari K, Pooga M, Hällbrink M,. The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J. 2009; 23: 214-223.
134. Niederhafner P, Reinis M, Sebestik J, Jezek J,. Glycopeptide dendrimers, part III-A review: use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J. Pept. Sci. 2008; 14: 556-587.
135. McGeary RP, Blanchfield JT, Rhee H, Chan Y-N, Alewood PF, Adams D, Toth I,. Enhancing peptide delivery using lipoamino acids and liposaccharides. In Innovation and Perspectives in Solid Phase Synthesis, Epton R, (ed.). Mayflower Worldwide Ltd: Birmingham, 2002; 169-172.
136. Perche F, Torchilin VP,. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Del. 2013; 705265. DOI: 10.1155/2013/705265.
137. Biswas S, Deshpande PP, Perche F, Dodwadkar NS, Namita S, Sane SD, Torchilin VP,. Octa-arginine-modified Pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett. 2013; 335: 191-200.
138. Biswas S, Torchilin VP,. Dendrimers for siRNA delivery. Pharmaceutics 2013; 6: 161-183.
139. Levchenko T, Hartner W, Torchilin VP,. Immunoliposomes for cardiovascular targeting. In Antibody-mediated Drug Delivery Systems, Pathak Y, Benita S, (ed.). 2012; 13-33.
140. Gupta B, Levchenko TS, Torchilin VP,. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Advanced Drug Del. Rev. 2005; 57: 637-651.
141. 32P]-labelled nucleotides. J. Biochem. Biophys. Methods 2004; 58: 111-117.
142. Wang H, Zhong C-Y, Wu J-F, Huang Y-B, Liu C-B,. Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J Control. Rel. 2010; 143: 64-70.
143. Gräslund A, Mäler L,. Testing membrane interactions of CPPs. Methods Mol. Biol. 2011; 683: 33-40.
144. Deshayes S, Konate K, Aldrian G, Crombez L, Heitz F, Divita G,. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake. Biochim. Biophys. Acta 2010; 1798: 2304-2314.
145. Arsov Z, Nemec M, Schara M, Johansson H, Langel Ü,. Cholesterol prevents interaction of the cell-penetrating peptide transportan with model lipid membranes. J. Pept. Sci. 2008; 14: 1303-1308.
146. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP,. Translocating prolin-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002; 41: 14150-14157.
147. Futaki S,. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Del. Rev. 2005; 57: 547-558.
148. Afonin S, Frey A, Bayerl S, Fischer D, Wadhwani P, Weinkauf S, Ulrich A,. The cell-penetrating peptide TAT (48-60) induces a non-lamellar phase in DMPC membranes. Chem Phys Chem 2006; 7: 2134-2142.
149. Cardoso AMS, Trabulo S, Cardoso AL, Lorents A, Morais CM, Gomes P, Nunes C, Lucio M, Reis S, Padari K, Pooga M, Pedroso de Lima MC, Jurado AS,. S4(13)-PV cell penetrating peptide induces physical and morphological changes in membrane-mimetic lipid systems and cell membranes: Implications for cell internalization. Biochim. Biophys. Acta 1818; 2012: 877-888.
150. Barany-Wallje E, Keller S, Serowy S, Geibel S, Pohl P, Bienert M, Dathe M,. A critical reassessment of penetratin translocation across lipid membranes. Biophys. J. 2005; 89: 2513-2521.
151. Wadhwani P, Reichert J, Bürck J, Ulrich A,. Antimicrobial and cell-penetrating peptides induce lipid vesicle fusion by folding and aggregation. Europ. Biophys. J. 2012; 41: 177-187.
152. Pujals S, Fernandez-Carneado J, Lopez-Iglesias C, Kogan MJ, Giralt E,. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta 2006; 1758: 264-279.
153. Kaplan IM, Wadia JS, Dowdy SF,. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Rel. 2005; 102: 247-253.
154. Yesylevsky S, Marrink S-J, Mark AE,. Alternative mechanisms for the interaction of the cell-penetrating peptides penetratin and the TAT peptide with lipid bilayers. Biophysical J. 2009; 97: 40-49.
155. Ghibaudi E, Boscolo B, Inserra G, Laurenti E, Traversa S, Barbero L, Ferrari RP,. The interaction of the cell-penetrating peptide penetratin with heparin, heparansulfates and phospholipid vesicles investigated by ESR spectroscopy. J. Pept. Sci. 2005; 11: 401-409.
156. Mellert K, Lamia M, Scheffzek K, Wittig R, Kaufmann D,. Enhancing endosomal escape of transduced proteins by photochemical internalisation. Plos one 2012; 7: e52473.
157. Briggs MS, Gierasch LM,. Molecular mechanism of protein secretion: the role of signal sequence. Adv. Protein Chem. 1986; 38: 109-180.
158. Faustin K, Monnanda B, Makou D, Capone S, Patora-Komisarska K, Seebach D,. On the mechanism of eukaryotic cell penetration by α- and β-oligoarginines-targeting infected erythrocytes. Chem. Biodivers. 2011; 8: 1-12.
159. Liu KY, Timmons S, Lin Y-Z,., Hawiger J, Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 11819-1824.
160. Fotin-Mieczek M, Welte S, Mader O, Duchardt F, Fischer R, Hufnagel H, Scheurich P, Brok R,. Cationic cell-penetrating peptides interfere with TNF signaling by induction of TNF receptor internalization. J. Cell Sci. 2005; 118: 3339-3351.
161. Zhang L, Torgerson TR, Liu X-Y, Timmons S, Colosia AD, Hawiger J, Tam JP,. Preparation of functionally active cell-permeable peptides by single-step ligation of two peptide modules. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 9184-9189.
162. Rojas M, Donahue JP, Tan Z, Lin Y-Z,. Genetic engineering of proteins with cell-membrane permeability. Nature Biotechnol. 1998; 16: 370-375.
163. Martin I, Dohmen C, Mas-Moruno C, Troiber C, Kos P, Schaffert D, Laechelt U, Teixido M, Guenther M, Kessler H,. Solid-phase-assisted synthesis of targeting peptide-PEG-oligo(ethane amino)amides for receptor mediated gene delivery. Org. & Biomol. Chem. 2012; 10: 3258-3268.
164. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A,. Activation and inhibition of G-protein coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. U. S. A. 2002; 98: 643-648.
165. Jean-Alphonse F, Hanyaloglu AC,. Regulation of GPCR signal networks via membrane trafficking. Mol. Cell. Endocrin. 2011; 331: 205-214.
166. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, Lebleu B,. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J. Control. Rel. 2006; 110: 595-604.
167. Wolf Y, Pritz F, Abes S, Bienert M, Lebleu B, Oehlke J,. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. Biochemistry 2006; 45: 14944-14954.
168. Hoyer J, Schatzschneider U, Schulz-Siegmund M, Neundorf I,. Dimerization of a cell-penetrating peptide leads to enhanced cellular uptake and drug delivery. Beilstein J. Org. Chem. 2012; 8: 1788-1797.
169. Anko M, Majhenc J, Kogej S, Sillard R, Langel Ü, Anderluh G, Zorko M,. Influence of stearyl and trifluoromethylquinoline modifications of the cell penetrating peptide TP10 on its interaction with a lipid membrane. Biochim. Biophys. Acta (Biomembranes) 2012; 1818: 915-924.
170. D'Souza-Schorey C, Chavrier P,. ARF proteins: roles in membrane traffic and beyond. Nat. Rev. Mol. Cell Biol. 2006; 7: 347-358.
171. Shiraishi T, Pankratova S, Nielsen P,. Calcium ions effectively enhance the effect of antisense peptide nucleic acids conjugated to cationic TAT and oligoarginine peptides. Chem. Biol. 2005; 12: 923-929.
172. Erazo-Oliveras A, Muthukrishnan N, Baker R, Wang T-Y, Pellois J-P,. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategy and challenges. Pharmaceutics 2012; 5: 1177-1209.
173. th American Peptide Symposium (Eds. Tam JP, Kaumaya PTP), 1999; 627-628.
174. Abbate V, Liang W, Patel J, Lan Y, Capriotti L, Iacobucci V, Bui TT, Chaudhuri P, Kudsiova L, Vermeer LS, Chan PFL, Kong X, Drake AF, Lam JKW, Bansal SS, Mason AJ,. Manipulating the pH response of 2,3-diaminopropionic acid rich peptides to mediate highly effective gene silencing with low toxicity. J. Control. Release 2013; 172: 929-938.
175. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, Melzig M, Bienert M,. Cellular uptake of an α-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1998; 1414: 127-139.
176. 13-PV cell penetrating peptide with model membranes: relevance to peptide translocation across biological membranes. J. Pept. Sci. 2007; 13: 301-313.
177. Shiraishi T, Nielsen PE,. Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates. FEBS Let. 2006; 580: 1451-1456.
178. Räägel H, Hein M, Kriiska A, Säälik P, Floren A, Langel Ü, Pooga M,. Cell-penetrating peptide secures an efficient endosomal escape of an intact cargo upon a brief photo-induction. Cell. Mol. Life Sci. 2013; 70: 4825-4839.
179. Szeto HH, Schiller PW, Zhao K, Luo G,. Fluorescent dyes alter intracellular targeting and function of cell-penetrating peptides. FASEB J. 2005; 19: 118-120.
180. Kalderon D, Richardson WD, Markham AF, Smith AE,. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature (London) 1984; 311 (5981): 33-38.
181. Goldfarb DS, Garipy J, Schoolnik G, Kornberg RD,. Synthetic peptides as nuclear localization signals. Nature 1986; 322: 641-644.
182. Hariton-Gazal E, Gilon C, Mor A, Loyter A,. A novel class of cell permeable karyophilic peptides: NLS-mediated nuclear import of dermaseptin derived peptides in intact cells. In Peptides: The Wave of the Future, Lebel M, Houghten RA, (ed.). American Peptide Society: San Diego, 2001; 959-960.
183. Matschke J, Bohla A, Maucksch C, Mittal R, Rudolph C, Rosenecker J,. Characterization of Ku702-NLS as bipartide nuclear localization sequence for non-viral gene delivery. PLoS One 2012; 7: e24615.
184. Fagerlund R, Melen K, Cao X, Julkunen J,. NF-κB p52, RelB and c-Rel are transported into the nucleus via a subset of importin α molecules. Cell. Signal. 2008; 20: 1442-1451.
185. Wang H-Y, Chen J-X, Sun Y-X, Deng J-Z, Li C, Zhang X-Z, Zhuo R-X,. Construction of cell penetrating peptide vectors with N-terminal stearylated nuclear localization signal for targeted delivery of DNA into cell nuclei. J. Control. Rel. 2011; 155: 26-33.
186. Makkerh JP, Dingwall C, Laskey RA,. Comparative mutagenesis of nuclear localization signals reveals the importance of neutral and acidic amino acids. Curr. Biol. 1996; 6: 1025-1027.
187. Kim B-K, Kang H, Doh K-O, Lee S-H, Park J-W, Lee S-J, Lee T-J,. Homodimeric SV40 NLS peptide formed by disulfide bond as enhancer for gene delivery. Bioorg. Medicin. Chem. Lett. 2012; 22: 5415-5418.
188. Dan Lewis H, Husain A, Donnely RJ, Barlos D, Riaz S, Ginjupalli K, Shodeinde A, Barton BE,. Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines. BMC Biotechnol. 2010; 10: 79. Doi: 1472-6750/10/79
189. Duverger E, Pellerin-Mendes C, Mayer R, Roche A-C, Monsigny M,. Nuclear import of glycoconjugates is distinct from classical NLS pathway. J. Cell Sci. 1995; 108: 1325-1332.
190. Rondanino C, Bousser M-T, Monsigny M, Roche A-C,. Sugar-dependent nuclear import of glycosylated proteins in living cells. Glycobiology 2003; 13: 509-519.
191. Radis-Baptista G, de la Torre BG, Andreu D,. A novel cell-penetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization. J. Med. Chem. 2008; 51: 7041-7044.
192. Kamena F, Monnanda B, Makou D, Capone S, Patore-Komisarska K, Seebach D,. On the mechanism of eukaryotic cell penetration by α- and β-oligoarginines-targeting infected erythrocytes. Chemistry and Biodiversity 2011; 8: 1-12.
193. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO,. Mitochondria-penetrating peptides. Chem. & Biol. 2008; 15: 375-382.
194. Yousif LF, Stewart KM, Horton KL, Kelley SO,. Mitochondria-penetrating peptides: sequence effects and model cargo transport. ChemBioChem 2009; 10: 2081-2088.
195. Kalafut D, Anderson TN, Chmielewski J,. Mitochondrial targeting of cationic amphiphilic polyproline helix. Bioorg. & Med. Chem. Lett. 2012; 22: 561-563.
196. Dekiwadia CD, Lawrie AC, Fecondo JV,. Peptide-mediated cell penetration and target delivery of gold nanoparticles into lysosomes. J. Pept. Sci. 2012; 18: 527-534.
197. Kallweit E, Tansi F, Kaether C, Kappe K, Schumann C, Hilger I, Reissmann S,. Internalization of a near infrared fluorescence labeled activatable cell-penetrating peptide and proteins into human fibrosarcoma cells HT-1080. J. Cell. Biochem. submitted.
198. Savanier EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P, Tsien RY, Nguen QT,. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res. 2013; 73: 855-864.
199. Mussbach F, Pietrucha R, Schaefer B, Reissmann S,. Internalization of nucleoside phosphates into live cells by complex formation with different cell penetrating peptides and JBS-Nucleoducin. Methods Mol. Biol. 2011; 683: 375-389.
200. Keller AA, Mussbach F, Breitling R, Hemmerich P, Schaefer B, Lorkowski S, Reissmann S,. Relationships between cargo, cell penetrating peptides and cell type for uptake of non-covalent complexes into live cells. Pharmaceutics 2013; 6: 184-203.
201. Rechenmacher F, Neubauer S, Polleux J, Mas-Moruno C, De Simone M, Calvalcanti-Adam EA, Spatz JP, Fässler R, Kessler H,. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro. Angew. Chem. Int. Ed. 2013; 52: 1572-1575.
202. Mizuno T, Miyashita M, Miyagawa H,. Cellular internalization of arginine-rich peptides into tobacco suspension cells: a structure-activity relationship study. J. Pept. Sci. 2009; 15: 259-263.
203. Svensen N, Diaz-Mochon JJ, Dhaliwal K, Planoth S, Dewar M, Armstrong JG, Bradley M,. Screening of combinatorial homing peptide library for selective cellular delivery. Angewandte Chemie Int. Ed. 2011; 50: 6133-6136.
204. Svensen N, Walton JGA, Bradley M,. Peptides for cell-selective drug delivery. Trends in Pharmacological Sci. 2012; 33: 186-192.
205. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY,. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell-penetrating peptides. Integrative Biol. 2009; 1: 371-381.
206. van Duijnhoven SMJ, Robillard MS, Nicolay K, Gruell H,. Tumor-targeting of MMP-2/9 activatable cell-penetrating probes is caused by tumor-independend activation. J. Nuclear Med. 2011; 52: 279-286.
207. Whitney M, Crisp JL, Olson ES, Aguerilla TA, Gross LA, Ellies LG, Tsien RY,. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J. Biol. Chem. 2010; 285: 22532-22541.
208. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, Tsien RY,. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 4317-4322.
209. Olson ES, Whitney MA, Friedman B, Aguilera TA, Crisp JL, Baik FM, Jiang T, Baird SM, Tsimikas S, Tsien RY, Nguyen QT,. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr. Biol. 2012; 4: 595-605.
210. Savanier EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P, Tsien RY, Nguen QT,. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res. 2013; 73: 855-864.
211. Whitney M, Savariar EN, Friedman B, Levin RA, Crisp JL, Glasgow HL, Lefkowitz R, Adams SR, Steinbach P, Nashi N,. Ratiometric activatable cell-penetrating peptides provide rapid in vivo readout of thrombin activation. Angewandte Chemie Int. Ed. 2013; 52: 325-330.
212. Polster BM, Arze R, Lyttle ML, Nicholls CG, Hudson D,. Solid phase synthesis of dual-labeled peptides: development of cell permeable calpain specific substrates. J. Pept. Res.& Therap. 2006; 13: 83-91.
213. Tekewe A, Saleh M, Kassaye M,. Proteins and peptides as targeting carriers in anticancer drug delivery. Int. J. Pharmaceutical Sci. & Res. 2013; 4: 1-18.
214. Musial-Siwek M, Karabadzhak AG, Andreev OA, Reshetnyak YK, Engelman DM,. Tuning the insertion properties of pHLIP. Biochim. Biophys. Acta 2010; 1798: 1041-1046.
215. Andreev OA, Engelman DM, Reshetnyak YK,. pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents. Mol. Membrane Biol. 2010; 27: 341-352.
216. Reshetnyak YK, Andreev OA, Segala M, Markin VS, Engelman DM,. Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 15340-15345.
217. Jin E, Zhang B, Sun X, Zhou Z, Ma X, Sun Q, Tang J, Shen Y, van Kirk E, Murdoch WJ,. Acid active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J. Amer. Chem. Soc. 2013; 135: 933-940.
218. Inoue M, Mukai M, Hamanaka Y, Tatsuta M, Hiraoka M,., Kizaka-Kondoh S, Targeting hypoxic cells with a protein prodrug is effective in experiment malignant ascites. Int. J. Onc. 2004; 15: 713-720.
219. Trentin D, Hall H, Wechsler S, Hubbell JA,. Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1α variant for local induction of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 2506-2511.
220. Hu Y, Qiao C, Lv M, Feng J, Yu M, Shen B, Zhang Q, Li Y,. Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody. BMC Research Notes 2012; 5: 336. DOI: 10.1186/1756-0500-5-336.
221. Splith K, Bergmann R, Pietzsch J, Neundorf I,. Specific targeting of hypoxic tumor tissue with nitroimidazole-peptide conjugates. ChemMedChem 2012; 7: 57-61.
222. Hu W, Splith K, Neundorf I, Merz K, Schatzschneider U,. Influence of the metal center and linker on the intracellular distribution and biological activity of organometal-peptide conjugates. J. Biol. Inorganic Chem. 2012; 17: 175-185.
223. Splith K, Hu W, Schatzschneider U, Gust R, Ott I, Onambele LA, Prokop A, Neundorf I,. Protease-activatable organometal-peptide bioconjugates with enhanced cytotoxicity on cancer cells. Bioconjugate Chem. 2010; 21: 1288-1296.
224. Liu Y, Zheng X, Cao Z, Xu W, Zhang J, Gong M,. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin. Int. J. Pharmaceutics 2012; 434: 209-214.
225. Bolhassani A, Safaiyan S, Rafati S,. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer 2011; 10: 1-20.
226. Wang HY, Wang R-F,. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signalling. Adv. Immunol. 2012; 114: 151-156.
227. Dietz G,. Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research. Curr. Pharm. Biotechnol. 2010; 11: 167-174.
228. Zhao B, Wang J, Zhang Y, Li Y, Zhang X, Xu Y, Chen L, Li C, Ju Y, Meng S,. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and anti-tumor T-cell responses. Vaccine 2013; 31: 545-552.
229. Weisbart R, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN,. Cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets. Mol. Cancer Therapeutics 2012; 11: 2169-2173.
230. Weisbart RH, Wakelin R, Chan G, Miller CW, Koeffler PH,. Construction and expression of bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int. J. Oncology 2004; 25: 1113-1118.
231. Arbel M, Solomon B,. Immunotherapy for Alzheimer's disease: attacking amyloid-β from the inside. Trends Immunol. 2007; 28: 511-513.
232. Clohisy JC, Roy BC, Bhabesh C, Biondo C, Frazier E, Willis D, Teitelbaum SL, Abu-Amer J,. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J. Immunol. 2003; 171: 5547-5553.
233. Orange JS, May MJ,. Cell penetrating peptide inhibitors of nuclear factor kappa-B. Cell. Mol. Life Sci. 2008; 65: 3564-3591.
234. Boisguerin P, Red-Clouet C, Franck-Miclo A, Licheheb S, Nargeot J, Barrere-Lemaire S, Lebleu B,. Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries in vivo. J. Control. Rel. 2011; 156: 146-153.
235. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J,. In vivo delivery of Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 2002; 22: 5423-5431.
236. Borsello T, Clarke PGH, Lorenz H, Vercelli A, Repici M, Schoderet DF, Bogousslavsky J, Bonny C,. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003; 9: 1180-1186.
237. Mussbach F, Martin F, Zoch A, Schaefer B, Reissmann S,. Tranduction of peptides and proteins into live cells by cell penetrating peptides. J. Cell. Biochem. 2011; 112: 3824-3833.
238. Keller AA, Mussbach F, Breitling R, Hemmerich P, Kappe K, Wittig B, Braun M, Schaefer B, Lorkowski S, Reissmann S,. Transduction of proteins into Leishmania tarentolae by formation of non-covalent complexes with cell-penetrating peptides. J. Cell. Biochem. 2014; 115: 243-252.
239. Dunican DJ, Doherty P,. Designing cell-permeant phosphopeptides to modulate intracellular signal pathways. Biopolymers (Peptide Science) 2001; 60: 45-60.
240. Borysowski J, Gorski A,. Fusion to cell-penetrating peptides will enable lytic enzymes to kill intracellular bacteria. Med. Hypotheses 2010; 74: 164-166.
241. Zelman-Femiak M, Wang K, Gromova KV, Knaus P, Harms GS,. Covalent quantum dot receptor linkage via acyl carrier protein for single-molecule tracking, internalization, and trafficking studies. Biotechniques 2010; 49: 574-579.
242. Zhou M, Ghosh I,. Quantum dots and peptides: a bright future together. Biopolymers (Pept. Sci) 2006; 88: 325-339.
243. Pujals S, Bastus NG, Pereiro E, Lopez-Iglesias C, Puntes VF, Kogan MJ, Giralt E., Shuttling gold nanoparticles into tumoral cells with an amphipathic proline-rich peptide. ChemBioChem 2009; 10: 1025-1031.
244. Ruzza P, Donella-Deana A, Calderan A, Brunati A, Massimino ML, Elardo S, Mattiazo A, Pinna LA, Borin G,. Antennapedia/HS1 chimeric phosphotyrosyl peptide: conformational properties, binding capability to c-Fgr SH2 domain and cell permeability. Biopolymers (Peptide Science) 2001; 60: 290-306.
245. th European Peptide Symposium (Eds.: Leble M, Meldal M, Jensen KJ, Hoeg-Jensen T), European Peptide Society, 2010; 210-211.
246. Yu J, Taylor L, Mierke D, Berg E, Shia M, Fishman J, Sallum C, Polgar P,. Limiting angiotensin-II signalling with a cell-penetrating peptide mimicking the second intracellular loop of the angiotensin II type-I receptor. Chem. Biol. Drug Des. 2010; 76: 70-76.
247. Inagaki K, Hahn HS, Dorn GW, Mochly-Rosen D,. Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ε-protein kinase C activator. Circulation 2003; 108: 869-875.
248. Krosl J, Austin P, Beslu N, Kroon E, Humphries RK, Sauvageau G,. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat. Med. 2003; 9: 1428-1432.
249. Turner JJ, Ivanova GD, Verbeure B, Williams D, Arzumanov AA, Abes S, Lebleu B, Gait MJ,. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 TAT-dependent trans-activation in cells. Nucleic Acids Res. 2005; 33: 6837-6849.
250. Morris MC, Gros E, Aldrian-Herrada G, Choob M, Archdeacon J, Heitz F, Divita G,. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res. 2007; 35: e49.
251. Nielsen PE,. Peptide nucleic acids (PNA) in chemical biology and drug discovery. Chem. Biodivers. 2010; 7: 786-804.
252. Andaloussi S, Lehto T, Lundin P, Langel Ü,. Application of PepFect peptides for the delivery of splice-correcting oligonucleotides. Methods Mol. Biol. 2011; 683: 361-373.
253. Yin HF, Moulton HM, Betts C, Merritt T, Seow Y, Ashraf S, Wang QS, Boutilier J, Wood MJ,. Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol. Therapy 2010; 18: 1822-1829.
254. Moulton HM, Wu B, Jearawirlyapaisarn N, Sazani P, Lu QL, Kole R,. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Annals New York Acad. Sci. 2009; 1175 (Oligonucleotide Therapeuti cs): 55-60.
255. Moulton HM,. In vivo delivery of morpholino oligos by cell-penetrating peptides. Curr. Pharm. Des. 2013; 19: 2963-2969.
256. Moulton HM, Moulton JD,. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta (Biomembranes) 2010; 1798: 2296-2303.
257. Crombez L, Divita G,. A non-covalent peptide-based strategy for siRNA delivery. Methods Mol. Biol. 2011; 683: 349-360.
258. Hu W, Splith K, Neundorf I, Merz K, Schatzschneider U,. Influence of the metal center and linker on the intracellular distribution and biological activity of organometal-peptide conjugates. J. Biol. Inorganic Chem. 2012; 17: 175-185.
259. Crombez L, Charnet MC, Morris G, Aldrian-Herrada G, Heitz F, Divita G,. A non-covalent peptide-based strategy for siRNA delivery. Biochemical Soc. Transactions 2007; 35: 44-46.
260. Meade BR, Dowdy SF,. Enhancing the cellular uptake of siRNA duplexes following noncovalent packing with protein transduction domain peptides. Adv. Drug Del. Rev. 2008; 60: 530-536.
261. Hoyer J, Neundorf I,. Knockdown of G protein-coupled receptor through efficient peptide-mediated siRNA delivery. J. Control. Rel. 2012; 161: 826-834.
262. 413-PV cell-penetrating peptide and cationic liposomes act synergistically to mediate intracellular delivery of plasmid DNA. J. Gene Med. 2008; 10: 1210-1222.
263. Splith K, Hu W, Schatzschneider U, Gust R, Ott I, Onambele LA, Prokop A, Neundorf I,. Protease-activatable organometal-peptide bioconjugates with enhanced cytotoxicity on cancer cells. Bioconjugate Chem. 2010; 21: 1288-1296.
264. Dai YH, Liu BR, Chiang HJ, Lee HJ,. Gene transport and expression by arginine-rich cell-penetrating peptides in Paramecium. Gene 2011; 489: 89-97.
265. Rennert R, Neundorf I, Jahnke H-G, Suchowerskyj P, Dornaud P, Robitzki A, Beck-Sickinger A,. Generation of carrier peptides for the delivery of nucleic acid drugs in primary cells. ChemMedChem 2008; 3: 241-253.
266. Ribeiro S, Mairhofer J, Madeira C, Diogo MM, Lobato de Silva C, Monteiro G, Grabherr R, Cabral JM,. Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cell. Reprogram. 2012; 14: 13-137.
267. Cohen RN, van der Aa MAEM, Macaraeg N, Lee AO, Szoka FC, jr,. Quantification of plasmid DNA copies in the nucleus after lipoplex and polyplex transfection. J. Control. Rel. 2009; 135: 166-174.
268. Lentacker I, Vanderbroucke RE, Lucas B, Demeester J, De Smedt SC, Sanders NN,. New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. J. Control. Rel. 2008; 132: 279-288.
269. Mannisto M, Reinisalo M, Ruponen M, Honkaskoski P, Tammi M, Urtti A,. Polyplex-mediated gene transfer and cell cycle: effect of carrier on cellular uptake and intracellular kinetics, and significance of glycosaminoglycans. J. Gene Med. 2007; 9: 479-487.
270. Niederhafner P, Sebestik J, Jezek J,. Peptide dendrimers. J. Pept. Sci. 2005; 11: 757-788.
271. Sebestik J, Niederhafner P, Jezek J,. Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications. Amino Acids 2011; 40: 301-370.
272. Jezek J, Darton NJ, Derham BK, Royle N, Simpson J,. Biopharmaceutical formulations for pre-filled delivery devices. Expert Opinion in Drug Del. 2013; 10: 811-828.
273. Crombez L, Morris MC, Deshayes S, Heitz F, Divita G,. Peptide based nanoparticles for ex vivo and in vivo drug delivery. Current Pharmac. Design 2008; 14: 3656-3665.
274. Morris MC, Deshayes S, Heitz F, Divita G,. Cell-penetrating peptides: from molecular mechanism to therapeutics. Biol. Cell 2008; 100: 201-217.
275. Turner JJ, Arzumanov AA, Gait MJ,. Synthesis, cellular uptake and HIV-1 TAT-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res. 2005; 33: 27-42.
276. Koppelhus U, Shiraishi T, Zachar V, Pankratova S, Nielsen PE,. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjugate Chem. 2008; 19: 1526-1534.
277. Ryves WJ, Harwood AJ,. Use of a penetratin-linked peptide in Dictyostelium. Mol. Biotechnology 2006; 33: 123-137.
278. Suresh A, Kim Y-C,. Translocation of cell penetrating peptides on Chlamydomonas reinhardtii. Biotechnol. Bioeng. 2013; 110: 2795-2801.
279. Palm C, Netzereab S, Hällbrink M,. Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects. Peptides 2006; 27: 1710-1716.
280. Nekhotiaeva N, Elmquist A, Rajarao GK, Hällbrink M, Langel Ü, Good L,. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J. 2004; 18: 394-396.
281. Manoeur AP, Audet J,. Measurement of cell-penetrating peptide-mediated transduction of adult hematopoetic stem cells. Methods in Molecular Biology (Stem Cells in Regenerative Medicine) 2009; 482: 43-54.
282. Jones S, Lukanowska M, Suhorutsenko J, Oyenham S, Barratt C, Publicover S, Copolovici DM, Langel Ü, Howel J,. Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility. Hum. Reprod. 2013; 28: 1874-1889.
283. Dietz GPH, Bähr M,. Peptide-enhanced cellular internalization of proteins in neuroscience. Brain Res. Bulletin 2005; 68: 103-114.
284. Herve F, Ghinea N, Scherrmann J-M,. CNS delivery via adsorptive transcytosis. AAPS J. 2008; 10: 455.
285. ÓCallaghan K, Lee L, Nguen N, Hsieh M-Y, Kaneider NC, Klein AK, Sprague K, van Etten RA, Kuliopulos A, Covic L,. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 2012; 119: 1717-1725.
286. Rodrigues M, de la Torre BG, Andreu D, Santos NC,. Kinetic uptake profiles of cell penetrating peptides in lymphocytes and monocytes. Biochim. Biophys. Acta (General Subjects) 1830; 2013: 4554-4563.
287. Müller J, Triebus J, Kretschmar I, Volkmer R, Boisguerin P,. The agony and choice: how to find a suitable CPP for cargo delivery. J. Pept. Sci. 2012; 18: 293-301.
288. Aussedat B, Sagan S, Chassaing G, Bolbach G, Burlina F,. Quantification of the efficiency of cargo delivery by peptidic and pseudo-peptidic Trojan carriers using MALDI-TOF mass spectrometry. Biochim. Biophys. Acta 2006; 1758: 375-383.
289. Verdurmen WPR, Brok R,. Biological responses towards cationic peptides and drug carriers. Trends Pharmacol. Sci. 2011; 32: 116-124.
290. Gitton Y, Tibaldi L, Dupont E, Levi G, Joliot A,. Efficient CPP-mediated Cre protein delivery to developing and adult CNS tissues. BMC Biotechnol. 2009; 9: 40. DOI: 10.1186/1472-6750-9-40.
291. Rothbard JB, Jones LR,. Quantification of cellular and topical uptake of luciferin-oligoarginine conjugates. Methods Mol. Biol. 2011; 683: 487-504.
292. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladriere L, Allaman-Pillet N, Poirot O, Kellenberger S, Beckmann JS, Eizirik DI, Bonny C, Maurer F,. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. Biochim. Biophys. Acta (Biomembranes) 2007; 1768: 2222-2234.
293. Tünnemann G, Ter-Avetisyan G, Martin RM, Stöckl M, Herrmann A, Cardoso C,. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J. Pept. Sci. 2008; 14: 469-473.
294. Saar K, Lindgren M, Hansen M, Eiriksdottir E, Jiang Y, Rosenthal-Aizman K, Sassian M, Langel Ü,. Cell-penetrating peptides: a comparative membrane toxicity study. Anal. Biochem. 2005; 345: 55-65.
295. Niles AL, Moravec RA, Hesselberth PE, Scurria MA, Daily WJ, Riss TL,. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal. Biochem. 2007; 366: 197-206.
296. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM,. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 1992; 148: 2207-2216.
297. Verdurmen WPR, Thanos M, Ruttekolk IR, Gulbins E, Brok R,. Cationic cell-penetrating peptides induce ceramide formation via acid sphingomyelinase: implications for uptake. J. Control. Rel. 2010; 147: 171-179.
298. Gerbal-Chaloin S, Gondeau C, Aldrian-Herada G, Heitz F, Gauthier-Rouviere C, Divita G,. First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network remodelling. Biol. Cell 2007; 99: 223-238.
299. Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL, Moulton HM,. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res. 2007; 35: 5182-5191.
300. Liu X, Liu C, Zhang W, Xie C, Wei G, Lu W,. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int. J. Pharmaceutics 2013; 448: 159-167.
301. Kamei N, Nielsen EJB, Khafagy E-S, Takeda-Morishita M,. Noninvasive insulin delivery: the great potential of cell-penetrating peptides. Ther. Deliv. 2013; 4: 315-326.
302. Kamei N, Kikuchi S, Takeda-Morishita M, Teraswa Y, Yasuda A, Yamamoto S, Ida N, Nishio R, Takayama K,. Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self organizing maps. J. Pharmaceutical Sci. 2013; 102: 469-479.
303. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA,. Conjugation of arginine oligomers to cyclosporine A facilitates topical delivery and inhibition of inflammation. Nature Med. 2000; 6: 1253-1257.
304. Mueller NH, Ammar DA, Petrash JM,. Cell penetration peptides for enhanced entry of αB-crystallin into lens cells. Investigative Ophthalmology & Visual Sci. 2013; 54: 2-8.
305. Mäe M, Rautsi O, Enbäck J, Hällbrink M, Aizman KR, Lindgren M, Laakkonen P, Langel Ü,. Tumour targeting with rationally modified cell-penetrating peptides. Int. J. Pept. Res. & Ther. 2012; 18: 361-371. DOI: 10.1007/s10989-012-9312-1.
306. Matsumoto T,. Membrane destabilizing activity of influenca virus hemagglutinin-based synthetic peptide: implication of critical glycine residue in fusion peptide. Biophys. Chem. 1999; 79: 153-162.
307. Constantini DL, Hu M, Reilly RM,. Update peptide motifs for insertion of radiolabeled biomolecules into cell and routing the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother. Radiopharm. 2008; 23: 3-24.
308. Moulton HM,. Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers. Methods in Molecular Biology (Exon Skipping) 2012; 867: 407-414.
309. Akdag IO, Ozkirimli E,. The uptake mechanism of the cell-penetrating pVEC peptide. J. Chem. 2013; 851915. DOI: 10.1155/2013/851915.
310. Elmquist A, Hansen M, Langel Ü,. Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochim. Biophys. Acta 2006; 1758: 721-729.
311. Lin Y-Z, Yao SY, Veach RA, Torgerson TR, Hawiger J,. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell-permeable motif and nuclear localization sequence. J. Biol. Chem. 1995; 270: 14255-14258.
312. Eckmann CR, Neunteufel A, Pfaffstetter L, Jantsch MF,. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol. Biol. Cell 2001; 12: 1911-1924.
313. Kaasch AJ, Joiner KA,. Protein-targeting determinants in the secretory pathway of apicomplexan parasites. Curr. Opin. Microbiol. 2000; 3: 422-428.
314. Snyder EL, Meade BR, Saenz CC, Dowdy SF,. Treatment of terminal peritoneal carcinomatosis by transducible p53 activating peptide. PLoS Biol. 2004; 2: 186-193.
315. Fernandez-Lamazares AI, Adan J, Mitjans F, Spengler J, Albericio F,. Tackling lipophilicity of peptide drugs: replacement of the backbone N-methyl group of cilengitide by N-oligoethylene glycol (NOEG) chains. Bioconjugate Chem. 2014; 25: 11-17.
316. Elliot G, ÓHare P,. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233.